News Sentiment

ACTU sentiment intelligence

Actuate Therapeutics, Inc. Common stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.44 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 60

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+19.0% over one week, -30.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Johnson & Johnson stock trades steadily as diversified healthcare earnings and pipeline support long

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 19.0% Price confirming higher
Trend fit Trend inactive -30.4% over four weeks
Fair value -77.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 34
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 60
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 6
Quiver Quantitative 5
www.marketscreener.com 4
TradingKey 4
GlobeNewswire 4
Stock Titan 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 21
Analyst action 6
Regulatory and legal 2
Macro sensitivity 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 67
Investing.com India Direct company coverage

Actuate Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com

Actuate Therapeutics, Inc. held its annual meeting, electing Aaron G.L. Fletcher, Ph.D., and Jason Keyes as Class II directors for three-year terms and ratifying Crowe LLP as its independent auditor. The company, trading at $2.38 with a market cap of $57.9 million, has declined 7

Tone
Positive 65/100
Event
Market update
Published
23 May 2026 21:40
Source
Investing.com India
Minichart Direct company coverage

Actuate Therapeutics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing

Actuate Therapeutics, Inc. (NASDAQ: ACTU) filed a Form 8-K with the SEC on May 21, 2026, detailing the results of a shareholder vote, which showed strong support for the election of directors. The filing confirms the company's status as a Delaware corporation, its listing on NASD

Tone
Neutral 50/100
Event
Earnings
Published
23 May 2026 10:39
Source
Minichart
Investing.com Direct company coverage

Actuate Therapeutics elects directors and ratifies auditor at annual meeting

Actuate Therapeutics (NASDAQ:ACTU) held its annual meeting where shareholders elected Aaron G.L. Fletcher, Ph.D., and Jason Keyes as Class II directors, and ratified Crowe LLP as the independent auditor for the fiscal year ending December 31, 2026. Despite a significant share pri

Tone
Positive 63/100
Event
Market update
Published
22 May 2026 21:10
Source
Investing.com
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Pyxis Oncology (PYXS) with a $6.00 price target, highlighting a strong buy consensus among analysts. H.C. Wainwright analyst Swayampakula Ramakanth also maintained a Buy rating on Actuate Therapeutics, Inc. (ACTU) wit

Tone
Positive 72/100
Event
Analyst action
Published
21 May 2026 09:09
Source
The Globe and Mail
Moomoo Direct company coverage

Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

HC Wainwright & Co. has reiterated its Buy rating for Actuate Therapeutics, maintaining a price target of $15.00 per share. This indicates continued confidence in the company's financial prospects and potential stock performance according to the analyst firm.

Tone
Positive 60/100
Event
Analyst action
Published
18 May 2026 18:39
Source
Moomoo
BioSpace Direct company coverage

Can Revolution’s 'miracle' pancreatic cancer drug be topped? Immuneering, Actuate say yes

Revolution Medicines' RAS inhibitor recently doubled survival in a Phase 3 pancreatic cancer trial, a significant breakthrough for a deadly disease. However, companies like Immuneering, Actuate Therapeutics, and Erasca are developing alternative approaches focusing on improved to

Tone
Positive 85/100
Event
Market update
Published
18 May 2026 14:11
Source
BioSpace